Lineage Cell Therapeutics Inc [AMEX: LCTX] price plunged by -16.02 percent to reach at -$0.1.
The one-year LCTX stock forecast points to a potential upside of 88.01. The average equity rating for LCTX stock is currently 1.43, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Lineage Cell Therapeutics Inc [LCTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LCTX shares is $4.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LCTX stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Craig Hallum have made an estimate for Lineage Cell Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 20, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 02, 2022, representing the official price target for Lineage Cell Therapeutics Inc stock. Previously, the target price had yet another raise to $4, while B. Riley Securities analysts kept a Buy rating on LCTX stock.
The Average True Range (ATR) for Lineage Cell Therapeutics Inc is set at 0.08, with the Price to Sales ratio for LCTX stock in the period of the last 12 months amounting to 9.16. The Price to Book ratio for the last quarter was 1.44, with the Price to Cash per share for the same quarter was set at 0.21.
LCTX Stock Performance Analysis:
Lineage Cell Therapeutics Inc [LCTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -41.71. With this latest performance, LCTX shares dropped by -41.14% in over the last four-week period, additionally sinking by -52.01% over the last 6 months – not to mention a drop of -49.61% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LCTX stock in for the last two-week period is set at 22.51, with the RSI for the last a single of trading hit 16.29, and the three-weeks RSI is set at 27.45 for Lineage Cell Therapeutics Inc [LCTX]. The present Moving Average for the last 50 days of trading for this stock 0.8668, while it was recorded at 0.7056 for the last single week of trading, and 1.0099 for the last 200 days.
Insight into Lineage Cell Therapeutics Inc Fundamentals:
Lineage Cell Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.48 and a Current Ratio set at 2.48.
Lineage Cell Therapeutics Inc [LCTX] Institutonal Ownership Details
There are presently around $50.56%, or 50.79%% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 41.67 million shares, which is approximately 22.7798%. BLACKROCK INC., holding 9.56 million shares of the stock with an approximate value of $$9.53 million in LCTX stocks shares; and BLACKROCK INC., currently with $$8.45 million in LCTX stock with ownership which is approximately 4.6329%.
